Search Results - "James, Izanec"

S736 Identifying the Optimal Treatment Sequence for Ustekinumab in Treatment Algorithms for Advanced Therapies in Ulcerative Colitis by Zhang, Suyuan, Dimova, Mariya, Teeple, Amanda, Ding, Zhijie, Muser, Erik, Izanec, James L.

Get full text

S723 Improvements in Work Productivity Loss and Associated Cost Reductions with Ustekinumab and Adalimumab in Biologic-Naïve Patients with Moderately-to-Severely Active Crohn’s Disease: Results From the SEAVUE Study by Ding, Zhijie, Muser, Erik, Hoops, Timothy, Izanec, James L., Ma, Tony, Gao, Long-Long, Gasink, Christopher

Get full text

S722 Real World Effectiveness of Ustekinumab in Patients With Crohn’s Disease: Findings From a Survey of Gastroenterologists in the U.S by Ding, Zhijie, Muser, Erik, Izanec, James L., Wild, Rosie, Lukanova, Rina, Kershaw, Jim, MEnv

Get full text

S851 Health-Related Quality of Life With Ustekinumab vs Adalimumab for Induction and Maintenance Therapy in Biologic-Naïve Patients With Moderate-To-Severe Crohn’s Disease: PROMIS-29 in the SEAVUE Study by Lewis, James D., Allez, Matthieu, Irving, Peter M., Hoops, Timothy, Izanec, James L., Ma, Tony, Ding, Zhijie, Muser, Erik, Gasink, Christopher, Panaccione, Remo, Loftus, Edward V., Danese, Silvio, Sands, Bruce E.

Get full text

S770 Health-Related Quality of Life With Ustekinumab vs Adalimumab for Induction and Maintenance Therapy in Biologic-Naïve Patients With Moderate-To-Severe Crohn’s Disease: IBDQ in the SEAVUE Study by Loftus, Edward V., Danese, Silvio, Panaccione, Remo, Hoops, Timothy, Izanec, James L., Ma, Tony, Ding, Zhijie, Muser, Erik, Gasink, Christopher, Irving, Peter M., Allez, Matthieu, Sandborn, William J.

Get full text

S1290 Efficacy, Safety, and Pharmacokinetics of Infliximab Dose Escalation in Pediatric Patients With Crohn’s Disease or Ulcerative Colitis: An Analysis of the DEVELOP Registry by Dubinsky, Marla C., Markowitz, James, Busse, Christopher, Koletzko, Sibylle, Winter, Harland, Baldassano, Robert, Colletti, Richard, Kugathasan, Subra, Ruemmele, Frank, Griffiths, Anne, Gasink, Christopher, Adedokun, Omoniyi, Izanec, James L., Gao, Long-Long, Ma, Tony, Ott, Elyssa, Hyams, Jeffrey

Get full text

Trends in US emergency department visits and subsequent hospital admission among patients with inflammatory bowel disease presenting with abdominal pain: a real-world study from a national emergency department sample database by Ding, Zhijie, Patel, Aarti, Izanec, James, Pericone, Christopher D., Lin, Jennifer H., Baugh, Christopher W.

“…Background/Objective: This study evaluated emergency department (ED) visit trends, subsequent inpatient admissions for patients with inflammatory bowel disease…”
Get full text

775d Ustekinumab Versus Adalimumab for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE Study by Sands, Bruce E., Irving, Peter M., Hoops, Timothy, Izanec, James L., Gao, Long-Long, Gasink, Christopher, Greenspan, Andrew, Allez, Matthieu, Danese, Silvio, Hanauer, Stephen B., Jairath, Vipul, Kuehbacher, Tanja, Lewis, James D., Loftus, Edward V., Mihaly, Emese, Panaccione, Remo, Scherl, Ellen J., Shchukina, Oksana, Sandborn, William J.

Get full text

Achalasia presenting after operative and nonoperative trauma by SHAH, Rupa N, IZANEC, James L, FRIEDEL, David M, AXELROD, Peter, PARKMAN, Henry P, FISHER, Robert S

“…Achalasia has been described following fundoplication and is attributed to vagal nerve damage during surgery. Similarly, other traumatic events to the distal…”
Get full text

P045 IS THE USE OF THIOPURINES WANING? INTERCONTINENTAL TRENDS REVEALED BY THE DEVELOP REGISTRY by Hyams, Jeffrey, Busse, Christopher, Wang, Yanli, Gasink, Christopher, Izanec, James

Get full text

P062 DOSE ESCALATION WITH ORIGINATOR INFLIXIMAB OR COMBINATION THERAPY WITH ORIGINATOR INFLIXIMAB AND IMMUNOMODULATORS SIGNIFICANTLY INCREASES RISK FOR SERIOUS ADVERSE EVENTS IN PEDIATRIC IBD – THE DEVELOP EXPERIENCE by Veereman, Gigi, Busse, Christopher, Wang, Yanli, Izanec, James

Get full text

Mechanics and hemodynamics of esophageal varices during peristaltic contraction by Miller, Larry S, Kim, Joseph K, Dai, Qing, Mekapati, Jyothi, Izanec, James, Chung, Chan, Liu, Ji-Bin, Sanderson, Andrew, Bohning, Matt, Desipio, Josh, Gandegok, Jasneet, Harberson, Justin J, Schneck, Carson, Nicosia, Mark A, Thangada, Vinod, Thomas, Beje, Copeland, Brian, Miller, Elan, Miller, Aaron, Ahmed, Naji, Brasseur, James G

“…Our hypothesis states that variceal pressure and wall tension increase dramatically during esophageal peristaltic contractions. This increase in pressure and…”
Get more information

S948 Relationship Between Hospitalization, Surgery and Achievement of Clinical Remission or Clinical Response in Moderate to Severe Crohn’s Disease Patients: Results From the UNITI/IM-UNITI Trials by Ding, Zhijie, Kachroo, Sumesh, Izanec, James, Naessens, Dominik, Fischer, Claire, Gauthier, Aline

Get full text

Long-term persistence and other treatment patterns among bio-naïve patients with Crohn’s disease treated with ustekinumab or adalimumab by Zhdanava, Maryia, Ding, Zhijie, Manceur, Ameur M., Zhao, Ruizhi, Holiday, Christopher, Kachroo, Sumesh, Izanec, James, Pilon, Dominic

“…OBJECTIVETo estimate long-term persistence among bio-naïve patients with CD initiated on ustekinumab or adalimumab. METHODSAdults with CD initiating…”
Get full text

S967 Real-World Prevalence of Potential Drug-Drug Interactions Associated With Oral Advanced Therapies Indicated for Ulcerative Colitis by Zhdanava, Maryia, Burbage, Sabree, Totev, Todor I., Kachroo, Sumesh, Diaz, Lilian, Godwin, Bridget, Lefebvre, Patrick, Izanec, James, Pilon, Dominic

“…Conclusion: In this descriptive analysis of patients with UC and moderate-to-severe UC, the prevalence of potential DDIs was higher for ozanimod than for JAK…”
Get full text

P062 DOSE ESCALATION WITH ORIGINATOR INFLIXIMAB OR COMBINATION THERAPY WITH ORIGINATOR INFLIXIMAB AND IMMUNOMODULATORS SIGNIFICANTLY INCREASES RISK FOR SERIOUS ADVERSE EVENTS IN PEDIATRIC IBD – THE DEVELOP EXPERIENCE by Veereman, Gigi, Busse, Christopher, Wang, Yanli, Izanec, James

“…Abstract Background DEVELOP is a multicenter, prospective, observational registry of the long-term safety and clinical status of 6070 pediatric patients with…”
Get full text

P045 IS THE USE OF THIOPURINES WANING? INTERCONTINENTAL TRENDS REVEALED BY THE DEVELOP REGISTRY by Hyams, Jeffrey, Busse, Christopher, Wang, Yanli, Gasink, Christopher, Izanec, James

“…Abstract Background Thiopurines (TP) have been a historical mainstay in the treatment of pediatric IBD since the 1990s. However, the advent of anti-TNF therapy…”
Get full text

Su1827 ALIGNMENT OF IBD SYMPTOMS REPORTED BY PATIENTS AND THEIR TREATING PHYSICIANS IN THE US by Ding, Zhijie, Muser, Erik, Obando, Camilo, Izanec, James L., Sikirica, Mirko, Lukanova, Rina, Meakin, Sophie

Get full text

S801 Long-Term Persistence to Ustekinumab and Adalimumab Among Bio-Naïve Patients With Crohn's Disease by Zhdanava, Maryia, Ding, Zhijie, Manceur, Ameur M., Kachroo, Sumesh, Holiday, Christopher, Zhao, Ruizhi, Izanec, James, Pilon, Dominic

Get full text

P037 Patterns of Care Among Patients Treated With Ustekinumab for Crohn’s Disease: Results From a Chart Review by Ruetsch, Charles, Davis, Tigwa, Clerie, Jennifer, Obando, Camilo, Izanec, James, Muser, Erik

“…BACKGROUND: Crohn’s Disease (CD) is a chronic, progressive disease that causes severe and debilitating symptoms often leading to hospitalizations and…”
Get full text